Tara Sanft, MD
Research & Publications
Biography
News
Research Summary
My research has centered around the patient experience during and after breast cancer treatment. I work with Melinda Irwin, PhD, MPH, Susan Dwight Bliss Professor of Epidemiology and Associate Dean of Research at the Yale School of Public Health.
Extensive Research Description
I conduct research with Dr. Melinda Irwin, and have completed several lifestyle intervention trials. I am the Principal Investigator of an NCI-funded R-01 study in which we randomize women to usual care or a healthy diet and exercise intervention in women undergoing chemotherapy for early stage breast cancer. We hope to find early intervention on lifestyle factors makes chemotherapy completion easier. Additionally, I am the site Principal Investigator of a study looking a resilience trajectories in patients diagnosed with breast, colon and prostate cancer, so that we may better learn who needs our help the most in order to thrive after cancer. I have mentored fellows on research projects including investigating decision-making for extended endocrine therapy in hormone receptor positive breast cancer; communication behaviors and patient experience during hospitalization on an oncology unit, exercise behaviors and chemotherapy completion rates and delivering survivorship education through an Enhancing Community Health Outcomes (ECHO) program.
Coauthors
Research Interests
Breast Diseases; Communication; Survivorship
Selected Publications
- NCCN Guidelines® Insights: Survivorship, Version 1.2022.Sanft T, Day A, Peterson L, Rodriguez MA, Ansbaugh S, Armenian S, Baker KS, Ballinger T, Broderick G, Demark-Wahnefried W, Dickinson K, Fairman NP, Friedman DL, Goldman M, Henry NL, Hill-Kayser C, Hudson M, Khakpour N, Koura D, McDonough AL, Melisko M, Mooney K, Moore HCF, Moryl N, Neuman H, O'Connor T, Overholser L, Paskett ED, Patel C, Pirl W, Porpiglia A, Ruddy KJ, Schapira L, Shockney L, Smith S, Syrjala KL, Tevaarwerk A, Yang EH, Zee P, McMillian NR, Freedman-Cass DA. NCCN Guidelines® Insights: Survivorship, Version 1.2022. Journal Of The National Comprehensive Cancer Network 2022, 20: 1080-1090. PMID: 36240847, DOI: 10.6004/jnccn.2022.0052.
- Factors associated with sleep health in young women after breast cancer treatmentHwang Y, Conley S, Jeon S, Redeker N, Sanft T, Knobf M. Factors associated with sleep health in young women after breast cancer treatment. Research In Nursing & Health 2022, 45: 680-692. PMID: 36102624, DOI: 10.1002/nur.22264.
- Engaging TEAM Medicine in Patient Care: Redefining Cancer Survivorship From Diagnosis.Alfano CM, Oeffinger K, Sanft T, Tortorella B. Engaging TEAM Medicine in Patient Care: Redefining Cancer Survivorship From Diagnosis. American Society Of Clinical Oncology Educational Book 2022, 42: 1-11. PMID: 35649204, DOI: 10.1200/edbk_349391.
- Weight gain after breast cancer diagnosis: It's complicated…Cathcart‐Rake E, Sanft T, Tevaarwerk AJ. Weight gain after breast cancer diagnosis: It's complicated…. Cancer 2022, 128: 3152-3154. PMID: 35781699, DOI: 10.1002/cncr.34343.
- Randomized trial of diet and exercise on chemotherapy completion in women with breast cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis (LEANer) study.Sanft T, Harrigan M, Cartmel B, Li F, Zupa M, McGowan C, Ferrucci L, Puklin L, Nguyen T, Tanasijevic A, Neuhouser M, Hershman D, Basen-Engquist K, Jones B, Knobf M, Chagpar A, Silber A, Ligibel J, Irwin M. Randomized trial of diet and exercise on chemotherapy completion in women with breast cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis (LEANer) study. Journal Of Clinical Oncology 2022, 40: 12007-12007. DOI: 10.1200/jco.2022.40.16_suppl.12007.
- Ancillary treatment referrals and visits after breast cancer surgery in a sociodemographically diverse population.Chan V, Heller D, Berger E, Capozza S, Greenup R, Sanft T. Ancillary treatment referrals and visits after breast cancer surgery in a sociodemographically diverse population. Journal Of Clinical Oncology 2022, 40: 1533-1533. DOI: 10.1200/jco.2022.40.16_suppl.1533.
- The Breast Cancer Index Registry Study: Initial analysis of the first 1,000 patients.O'Shaughnessy J, Encarnacion C, O'Neal B, Wong J, Siuliukina N, Sanft T, Jankowitz R, Pegram M, Treuner K, Fox J. The Breast Cancer Index Registry Study: Initial analysis of the first 1,000 patients. Journal Of Clinical Oncology 2022, 40: e12513-e12513. DOI: 10.1200/jco.2022.40.16_suppl.e12513.
- Establishing Goals of CareChoi A, Sanft T. Establishing Goals of Care. Medical Clinics Of North America 2022, 106: 653-662. PMID: 35725231, DOI: 10.1016/j.mcna.2022.01.007.
- 0590 Factors Associated with Sleep Health in Young Women After Breast Cancer TreatmentHwang Y, Conley S, Jeon S, Redeker N, Sanft T, Knobf M. 0590 Factors Associated with Sleep Health in Young Women After Breast Cancer Treatment. Sleep 2022, 45: a259-a260. DOI: 10.1093/sleep/zsac079.587.
- On CryingSanft T. On Crying. The Oncologist 2022, 27: 424-425. PMID: 35522560, PMCID: PMC9074966, DOI: 10.1093/oncolo/oyac043.
- Abstract OT1-10-01: The Breast Cancer Index registry study: A prospective multi-center observational study to evaluate patient outcome, clinical impact, and medication adherence in HR+ breast cancer patients considering treatment with extended endocrine therapyO'Shaughnessy J, Fox J, Encarnación C, O'Neal B, Treuner K, Sanft T, Jankowitz R, Pegram M, Schnabel C, Diab S. Abstract OT1-10-01: The Breast Cancer Index registry study: A prospective multi-center observational study to evaluate patient outcome, clinical impact, and medication adherence in HR+ breast cancer patients considering treatment with extended endocrine therapy. Cancer Research 2022, 82: ot1-10-01-ot1-10-01. DOI: 10.1158/1538-7445.sabcs21-ot1-10-01.
- Abstract PD13-03: Ribociclib, everolimus, exemestane triplet therapy in HR+/HER2− advanced breast cancer after progression on a CDK4/6 inhibitor: Final efficacy, safety, and biomarker results from TRINITI-1Hurvitz S, Clark A, Rugo H, Bardia A, Zelnak A, Yardley D, Karuturi M, Sanft T, Blau S, Hart L, Ma C, Purkayastha D, Eppig C, DeMichele A. Abstract PD13-03: Ribociclib, everolimus, exemestane triplet therapy in HR+/HER2− advanced breast cancer after progression on a CDK4/6 inhibitor: Final efficacy, safety, and biomarker results from TRINITI-1. Cancer Research 2022, 82: pd13-03-pd13-03. DOI: 10.1158/1538-7445.sabcs21-pd13-03.